Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Runimotamab intravenous dose-escalation study alone and with trastuzumab in advanced HER2-expressing cancers
NL-OMON60612Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of runimotamab and trastuzumab in HER2-positive breast cancer, sponsored by Genentech. Started Oct 2021; status: completed.
02
Drugs
runimotamabtrastuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NL-OMON60612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60612.